Immunohistochemistry (IHC) is a widely used technique for visualizing the presence and localization of specific cellular components in tissue samples. In drug discovery and development, IHC is used to profile tissues and determine biomarker expression, which can provide valuable insights into the mechanisms of drug action, toxicity, and resistance. However, traditional IHC has limitations when it comes to multiplexing – the ability to label multiple markers in the same sample. This is where Visikol’s Highly-Multiplexed Immunohistochemistry Services come in.
Visikol’s technology allows for the labeling of 10+ markers on a single slide and co-registration of multiple rounds of sequential labeling from the same slide. This means that pharmaceutical scientists can obtain unprecedented detail about samples, providing a more comprehensive understanding of tissue biology and drug activity. In this blog post, we will explore how Visikol’s Highly-Multiplexed Immunohistochemistry Services can revolutionize drug discovery and development.
The Limitations of Traditional IHC
Traditional IHC methods have been used for decades to visualize the presence and localization of proteins in tissue samples. These methods use a single primary antibody specific to the protein of interest, which is then detected using a secondary antibody conjugated to an enzyme or a fluorescent label. While this technique is useful for visualizing single proteins, it has limitations when it comes to multiplexing.
Multiplexing with traditional IHC requires the use of different primary antibodies, each with a unique detection system. This can lead to issues with cross-reactivity and background noise, making it difficult to obtain accurate and reproducible results. Additionally, traditional IHC methods are limited in the number of markers that can be labeled at once, typically no more than 3 or 4. This limitation makes it difficult to obtain a comprehensive understanding of tissue biology and drug activity.
The Advantages of Multiplex Immunohistochemistry
Multiplex immunohistochemistry (mIHC) overcomes the limitations of traditional IHC by allowing the labeling of multiple markers in the same sample. This technique is particularly useful for tissue profiling, where the expression of multiple biomarkers can provide valuable insights into tissue biology and drug activity.
Visikol’s Highly-Multiplexed Immunohistochemistry Services take mIHC to the next level, allowing for the labeling of 10+ markers on a single slide. This is achieved through the use of Visikol’s proprietary EasyPlex™ antibody stripping reagent and co-registration software, which enable multiple rounds of sequential labeling from the same slide. This means that multiple markers can be labeled and imaged in the same sample, providing unprecedented detail about tissue biology and drug activity.
How Multiplex Immunohistochemistry Can Revolutionize Drug Discovery
The ability to label multiple markers in the same sample provides pharmaceutical scientists with unprecedented insights into the mechanisms of drug action, toxicity, and resistance. By profiling tissues with Visikol’s Highly-Multiplexed Immunohistochemistry Services, scientists can obtain a more comprehensive understanding of how drugs interact with tissues and cells, allowing for the development of more effective drugs with fewer side effects.
Visikol’s technology is particularly useful for customized research, where clients can work with Visikol’s team to design a custom panel of markers to suit their research needs. This means that pharmaceutical scientists can obtain insights into specific pathways and mechanisms of interest, allowing for more targeted drug development.
Multiplex immunohistochemistry is a powerful tool for tissue profiling in drug discovery and development. Visikol’s Highly-Multiplexed Immunohistochemistry Services provide unprecedented detail about tissue biology and drug activity, allowing for more effective drug development with fewer side effects. By offering customized research services, Visikol is revolutionizing the field of tissue profiling and drug discovery.
If you’re interested in learning more about Visikol’s Highly-Multiplexed Immunohistochemistry Services, please reach out today!